RANI Share Price Performance
US$1.09
0.38 (53.91%)
90.1% undervalued intrinsic discount
US$11.00
Fair Value
Price US$1.09
AnalystHighTarget US$11.00
AnalystLowTarget US$5.00
AnalystConsensusTarget US$9.25
Fair ValueUS$11.00
Share Pricen/a
Rani Therapeutics Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
RANI Community Narratives
AN
Fair Value
·Fair Value US$11 90.1% undervalued intrinsic discount
Needle-Free Oral Biologics Will Serve Aging Global Demand
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$5 78.2% undervalued intrinsic discount
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$9.25 88.2% undervalued intrinsic discount
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Needle-Free Oral Biologics Will Serve Aging Global Demand
Key Takeaways Rani's oral therapy platform offers a significant adoption advantage and margin potential due to its non-invasive delivery and superior performance versus injections. Advancements in manufacturing and partnerships position the company for strong long-term growth while reducing reliance on dilutive financing.Read more
AN
US$11
90.1% undervalued intrinsic discount
Fair Value
Profit Margin
19.79%
Future PE
241.83x
Price in 2029
US$13.45
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?Read more
AN
US$5
78.2% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
181.36x
Price in 2029
US$6.12
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Key Takeaways RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue. Extensive patent portfolio and cost containment measures enhance protection, licensing opportunities, and improve net margins.Read more
AN
US$9.25
88.2% undervalued intrinsic discount
Fair Value
Profit Margin
20.87%
Future PE
227.34x
Price in 2028
US$11.27
Trending Discussion
Recently Updated Narratives
AN
RANI: Obesity Capsule Trial Progress Will Support Strong Future Upside Potential
Fair Value: US$11 90.1% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Fair Value: US$5 78.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RANI: Collaboration With Chugai And Cash Infusion Will Drive Future Upside
Fair Value: US$9.25 88.2% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Rani Therapeutics Holdings, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.29
- 100.00%
- -929.06%
- 0%
About RANI
- Founded
- 2012
- Employees
- 70
- CEO
- WebsiteView website
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai’s Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
